Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Asymchem Laboratories has opened its HPAPI and Drug Product facility in TEDA Tianjin, China.
May 21, 2009
By: Tim Wright
Editor-in-Chief, Contract Pharma
Asymchem Laboratories has opened its high potency Active Pharmaceutical Ingredient (API) and Drug Product facility in TEDA Tianjin, China. The dedicated facility is located at Asymchem’s TEDA Tianjin 1 location, and provides state-of-the art containment for production of potent API’s, as well as tablet and capsule manufacturing that incorporate potent ingredients. The new facility allows Asymchem to operate two separate API manufacturing trains of 50 and 100L, as well as additional facilities for smaller-scale research and production and oral dosage form manufacturing. “We are pleased to expand our capabilities in process research and manufacturing into the potent compound arena, and provide our partners with cost-effective and quality-driven means for undertaking this type of work in China,” said Dr. Hao Hong, Asymchem’s chief executive officer. Also, the company has named Dr. Chris Huber to the role of director of Chemical Development. Dr. Huber has more than 15 years of experience in the pharmaceutical industry, developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen and Arena Pharmaceuticals. Much of his career was spent in Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase III processes in preparation for commercial manufacturing of API. In his new role, Dr. Huber will help expand and strengthen Asymchem’s pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, vice president of Chemical Development. “I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem’s already well-established large scale manufacturing services,” Dr. Hong remarked. “With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !